Synthetic tripeptide bioregulator · Fact sheet
Pinealon
Also known as Glu-Asp-Arg · EDR peptide
Pinealon is the synthetic tripeptide Glu-Asp-Arg studied in cell and rat stress models. It is distinct from pineal extracts and has not established human neuroprotection, memory enhancement or a longevity regimen.
What is Pinealon?
The name refers to a defined three-amino-acid sequence in the cited studies.
The bioregulator label describes a research idea rather than a validated class of organ-restoring treatments.
Benefits & claims
Interest centers on brain function and sleep, aging and cellular function. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- Cell studies reported lower reactive oxygen species or altered survival under experimental stress.
- A maternal-rat model found changes in offspring cognition and isolated neurons.
- These designs do not establish benefit for human cognition or use during pregnancy.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Pinealon. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The name refers to a defined three-amino-acid sequence in the cited studies.
Formulation differences
- The bioregulator label describes a research idea rather than a validated class of organ-restoring treatments.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Human repeated-use, reproductive and neurologic safety have not been established.
- A favorable pregnancy-animal experiment cannot establish safety for a pregnant person or fetus.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchExperiments include oxidative-stress cell assays, prenatal hyperhomocysteinemia in rats and aging/hypoxia models. These are not clinical human cognitive trials.
Studies
Direct cell-culture oxidative-stress experiments.
Prenatal hyperhomocysteinemia rat model.
Aged-rat hypoxia/hypothermia experiment involving related preparations.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Pinealon has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.
- Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.
- [Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia].
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
These designs do not establish benefit for human cognition or use during pregnancy.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedPinealon increases cell viability by suppression of free radical levels and activating proliferative processes.
Direct cell-culture oxidative-stress experiments.
- pubmedPinealon protects the rat offspring from prenatal hyperhomocysteinemia.
Prenatal hyperhomocysteinemia rat model.
- pubmed[Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia].
Aged-rat hypoxia/hypothermia experiment involving related preparations.